Expression and Prognostic Value of ARID5A and its Correlation With Tumor-Infiltrating Immune Cells in Glioma.

Jingyi Fan,Jinping Zhou,Quan Zhou

doi:10.3389/fonc.2021.638803

Abstract

AT-rich interaction domain 5A (ARID5A) is a member of the ARID family with a function that has been linked to autoimmune as well as inflammatory diseases. Some ARID family members are involved in the initiation and progression of human cancers. However, the function of ARID5A in glioma remains unknown. In this study, ARID5A expression levels were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. Subsequently, the relationship between ARID5A expression and the clinical characteristics of glioma patients was evaluated using the Chinese Glioma Genome Atlas (CGGA) database and The Cancer Genome Atlas (TCGA) database. The prognostic value of ARID5A in glioma was estimated by Kaplan-Meier analysis and the receiver operating characteristic (ROC) curve analysis. Gene ontology (GO) analysis and gene set enrichment analysis (GSEA) were performed for functional prediction. The Tumor Immune Estimation Resource (TIMER) database was used to analyze the relationship between ARID5A and immune cell infiltration in glioma. Our results demonstrate that the expression of ARID5A was upregulated in glioma compared with that in nontumor brain tissues. High expression of ARID5A is associated with poor prognosis in glioma. We found that the expression of ARID5A was significantly upregulated with an increase in tumor malignancy. GO analysis revealed that co-expression genes of ARID5A are significantly involved in some important functions in glioma, and GSEA showed that multiple cancer-associated and immune-associated signaling pathways are enriched in the high ARID5A expression group. TIMER database indicated that ARID5A is correlated with tumor-infiltrating immune cells in glioma. Collectively, these findings indicate that ARID5A may be a potential prognostic biomarker and is correlated with immune infiltration in glioma.

Highlights

Glioma is a common intracranial malignant primary tumor, accounting for about 27% of all central nervous system tumors [1]
We analyzed the correlation between ARID5A expression and World Health Organization (WHO) grade, age, isocitrate dehydrogenase (IDH) mutation,1p/19q co-deletion in glioma patients based on Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) RNA sequencing data and clinical and molecular characterization data
receiver operating characteristic (ROC) curves were used to analyze the diagnostic value of the ARID5A gene in gliomas, and our results showed that the area under the curve (AUC) of ARID5A were 0.704, 0.740, and 0.736 for the CGGA datasets (Figure 5A) and 0.774, 0.753, and 0.730 for the TCGA datasets (Figure 5B) in 1, 3, and 5 years, respectively, indicating that the expression level of ARID5A had good diagnostic value for gliomas

Summary

Introduction

Glioma is a common intracranial malignant primary tumor, accounting for about 27% of all central nervous system tumors [1]. LGGs, grade II and III gliomas, show slow growth and low malignancy; GBM is an invasive-growing tumor with high recurrence and mortality and is defined as grade IV glioma [4, 5]. The rapid development of gene sequencing technology has led to the discovery of many molecular markers that play an important role in the occurrence and development of gliomas. This development in technology is of significance for the diagnosis and prognosis of gliomas, and these biomarkers are expected to be used as molecular targets to improve tumor therapy in the clinical treatment of patients. It is of great significance to identify biomarkers for determining cancer risk, estimating prognosis of patients, and predicting tumor recurrence

Methods

Results

Discussion

Conclusion